Streetbeat News

Price Targets

CING

HC Wainwright & Co. analyst Raghuram Selvaraju has reaffirmed a Buy rating on Cingulate (NASDAQ:CING) and increased the price target from $3.5 to $8, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 12:44 pm

APH

Citigroup analyst Asiya Merchant has initiated coverage on Amphenol (NYSE:APH) with a Buy rating and set a price target of $117.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 12:43 pm

NOG

Morgan Stanley analyst Devin McDermott has initiated coverage on Northern Oil & Gas (NYSE:NOG) with an Equal-Weight rating and set a price target of $40 for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 12:41 pm

ALKT

Needham analyst Mayank Tandon has reaffirmed a Buy rating on Alkami Technology (NASDAQ:ALKT) and increased the price target from $24 to $30.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 12:39 pm

NGNE

Stifel analyst Paul Matteis has initiated coverage on Neurogene (NASDAQ:NGNE) with a Buy rating and set a price target of $31.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 12:38 pm

BODY

Roth MKM analyst George Kelly has initiated coverage on Beachbody Co (NYSE:BODY) with a Buy rating and set a price target of $15.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 12:37 pm

IBM

Jefferies analyst Brent Thill has initiated coverage on IBM with a Hold rating and set a price target of $180.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 12:34 pm

MOND

Morgan Stanley analyst Brian Nowak has initiated coverage on Mondee Hldgs (NASDAQ:MOND) with an Equal-Weight rating and set a price target of $3.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 12:32 pm

SNOW

RBC Capital analyst Matthew Hedberg has initiated coverage on Snowflake (NYSE:SNOW) with an Outperform rating and set a price target of $230.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 12:31 pm

TRDA

Oppenheimer analyst Hartaj Singh has initiated coverage on Entrada Therapeutics (NASDAQ:TRDA) with an Outperform rating and set a price target of $22.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 12:23 pm